---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044760"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:02:49.028866+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ensysce reports Q3 net income of $0.7M; awarded $14M NIH grant for PF614-MPAR

## Summary
- Net income of $0.7M vs net loss of $2.7M in Q3 2023; driven by $3.4M in federal grant revenue.
- Cash & equivalents $4.2M at Sept 30, 2024, up from $1.1M at Dec 31, 2023; $8.5M raised in equity financings.
- Awarded $14M multi-year NIH grant for PF614-MPAR; second Phase 1b trial initiated.
- Pivotal PF614 Phase 3 protocol submitted to FDA; feedback expected by end of November.
- Stockholders' equity $6.6M, compliant with Nasdaq $2.5M listing requirement.

## SEC filing metadata
- accession: 0001493152-24-044760
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315224044760/0001493152-24-044760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315224044760/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044760
- JSON: https://secwatch.observer/filing/0001493152-24-044760.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044760.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.